{"id":3774,"date":"2022-07-14T07:29:45","date_gmt":"2022-07-14T07:29:45","guid":{"rendered":"https:\/\/www.value-dx.eu\/?p=3774"},"modified":"2022-07-14T07:29:45","modified_gmt":"2022-07-14T07:29:45","slug":"ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2","status":"publish","type":"post","link":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/","title":{"rendered":"Ecraid press release on European response to monkeypox virus outbreak"},"content":{"rendered":"\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-jzkylawd-ba86e75d702405f62001a756eb35483d\">\n.avia-section.av-jzkylawd-ba86e75d702405f62001a756eb35483d{\nbackground-color:#08b4a0;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_1'  class='avia-section av-jzkylawd-ba86e75d702405f62001a756eb35483d main_color avia-section-default avia-no-border-styling  avia-builder-el-0  el_before_av_section  avia-builder-el-first  avia-bg-style-parallax container_wrap fullsize'  ><div class='container av-section-cont-open' ><main  role=\"main\" itemprop=\"mainContentOfPage\"  class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-3774'><div class='entry-content-wrapper clearfix'>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-kx4q0z2f-b90c1f6ed66d46265d63e461d6c47700\">\n#top .av-special-heading.av-kx4q0z2f-b90c1f6ed66d46265d63e461d6c47700{\npadding-bottom:10px;\n}\nbody .av-special-heading.av-kx4q0z2f-b90c1f6ed66d46265d63e461d6c47700 .av-special-heading-tag .heading-char{\nfont-size:25px;\n}\n.av-special-heading.av-kx4q0z2f-b90c1f6ed66d46265d63e461d6c47700 .av-subheading{\nfont-size:15px;\n}\n<\/style>\n<div  class='av-special-heading av-kx4q0z2f-b90c1f6ed66d46265d63e461d6c47700 av-special-heading-h3 blockquote modern-quote modern-centered  avia-builder-el-1  el_before_av_codeblock  avia-builder-el-first  av-linked-heading'><h3 class='av-special-heading-tag '  itemprop=\"headline\"  >Ecraid press release on European response to monkeypox virus outbreak<\/h3><div class=\"special-heading-border\"><div class=\"special-heading-inner-border\"><\/div><\/div><\/div>\n\n\n<\/div><\/div><\/main><!-- close content main element --><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-1cjng-9db903d36b325f87b66fb9ba7e96614e\">\n.avia-section.av-1cjng-9db903d36b325f87b66fb9ba7e96614e{\nbackground-color:#1b7ca4;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_2'  class='avia-section av-1cjng-9db903d36b325f87b66fb9ba7e96614e main_color avia-section-default avia-no-border-styling  avia-builder-el-3  el_after_av_section  el_before_av_section  avia-bg-style-scroll container_wrap fullsize'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-3774'><div class='entry-content-wrapper clearfix'>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-k0i4yzrj-318dd765ad6f41d2fe86b741f8548ed0\">\n.flex_column.av-k0i4yzrj-318dd765ad6f41d2fe86b741f8548ed0{\nborder-radius:0px 0px 0px 0px;\npadding:50px 5% 50px 5%;\n}\n<\/style>\n<div  class='flex_column av-k0i4yzrj-318dd765ad6f41d2fe86b741f8548ed0 av_one_full  avia-builder-el-4  el_before_av_one_fifth  avia-builder-el-first  first flex_column_div  '     ><section  class='av_textblock_section av-yfjs-fd93b228aa1b13a89db4cc3964440224 '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock'  itemprop=\"text\" ><p><strong><img fetchpriority=\"high\" decoding=\"async\" class=\" wp-image-3769 alignleft\" src=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image-300x169.png\" alt=\"\" width=\"433\" height=\"244\" srcset=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image-300x169.png 300w, https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image-1030x579.png 1030w, https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image-768x432.png 768w, https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image-1536x864.png 1536w, https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image-1500x844.png 1500w, https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image-705x397.png 705w, https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image.png 1920w\" sizes=\"(max-width: 433px) 100vw, 433px\" \/><\/strong>Utrecht, 7 July 2022\u00a0\u2013\u00a0<em>Ecraid is assessing its readiness to respond in the event the monkeypox outbreak spreads further in Europe. These preparations are proportionate to the current relatively low risk of this infection for European citizens. Ecraid is currently operating in outbreak response mode 2 (mobilisation) for adults, and in outbreak response mode 1 (preparedness) for children, the second and first of three response modes.<\/em><\/p>\n<h3><strong>Outbreak<\/strong><\/h3>\n<p>Early May 2022 a multi-country outbreak of monkeypox virus (MPXV) started affecting the United Kingdom (UK), the EU\/EEA, Asia, the Americas, and Australia. The virus spreading outside of the known enzootic countries in the African region has been designated clade 3 MPXV. Cases that are thought to be linked to this outbreak have been reported from 31 countries and areas throughout the European region, and other countries. Most recognized infections are in men with high-risk exposure for transmission (men who have sex with men), and disease transmission outside this population is still rare, but there is some concern that expansion of the risk group is possible if the outbreak continues to evolve. The clinical manifestations of clade 3 MPXV infections are usually mild, and most people in the current outbreak have recovered within weeks. More severe disease has been reported in studies from African countries with enzootic presence of monkeypox, with outbreaks with clade 3 MPXV with a case-fatality rate up to 3% in Nigeria. The highest case fatality rates have been reported for children and young adults, as well as immunocompromised individuals.<\/p>\n<p>Treatment for monkeypox is mostly symptomatic. Tecovirimat was approved by the European Medicines Agency (EMA) for treatment of monkeypox throughout the EU on 6 January 2022. Tecovirimat has been authorised under \u2018exceptional circumstances\u2019, as it has not been possible to obtain complete information about tecovirimat efficacy and safety in human monkeypox due to the rarity of the disease. Persons with severe disease, immunocompromised patients, children younger than 8 years, and pregnant individuals could be considered for antiviral treatment.<\/p>\n<p>Although the exact extent of the outbreak remains to be established, these events have triggered an assessment of the level of preparedness of clinical research networks in Europe for possible deployment in case of further spread. The EU has invested in the development of these European clinical networks over many years to ensure preparedness for delivering clinical research in response to new infectious disease outbreaks. These networks include Ecraid: The European Clinical Research Alliance for Infectious Diseases (With the support of funding provided by the EU, Europe is now much better prepared to speed up the processes of clinical research to the extent that findings are generated in real time to inform practice when it is most useful, in the midst of an outbreak, rather than once the threat has passed.<\/p>\n<h3>How Ecraid is responding<\/h3>\n<p>Information on Ecraid&#8217;s response modes and implications can be found\u00a0<a href=\"https:\/\/www.prepare-europe.eu\/outbreakresponsemodes.html\" target=\"_blank\" rel=\"noopener noreferrer\">here<\/a>. Activities are planned and conducted in close collaboration with our partner networks (EU-RESPONSE and VACCELERATE) and the European Union and in alignment with those of WHO, ECDC and EMA. The preparations made by Ecraid as part of its mode 1 and 2 responses are briefly summarised below.<\/p>\n<p>Ecraid participates in the MOSAIC study (led by University of Oxford as the sponsor and ANRS\/Inserm representant of the sponsor in Europe). This is an observational study of the natural history of monkeypox disease in children and adults. With its collaborative network, Ecraid will identify study sites for participation in MOSAIC in those countries not yet participating. Together with its partners ANRS\/Inserm, University of Oxford and UMC Utrecht, the alliance also participates in the preparation of a randomized controlled trial evaluating the effectiveness of tecovirimat. Moreover, Ecraid offers countries access to serology and sequencing capacity in its network (e.g., Erasmus MC).<\/p>\n<p>Through its partners with expertise in pediatric infections (PENTA-ID, UMC Utrecht and Erasmus MC), Ecraid will develop a scientific research agenda in the event that monkeypox infections emerge in children. The first initiatives for preparation have focused on the use of Imvanex in adults and children as Post-Exposure Prophylaxis or Pre-Exposure Prophylaxis. Imvanex is not licensed for children under 18 years but is used off-label for exposed children. There is no standardized protocol for follow-up of these children and the possibilities of a cohort study looking at immunogenicity, break-through infections and adverse events is being explored with several European countries. Study developments will be discussed with EMA, and execution will be aligned with VACCELERATE.<\/p>\n<p>The standing Ecraid Outbreak Mode Committee (Prof. Marion Koopmans of the Erasmus Medical Center in Rotterdam, Prof. Peter Horby of the University of Oxford, Prof. Herman Goossens of the University of Antwerp, Prof. Yazdan Yazdanpanah and Prof. Marc Bonten, University Medical Center) continue to follow the events closely to ensure Ecraid\u2019s clinical research response remains aligned with the risk to health and security of European citizens.<\/p>\n<h3>Quotes<\/h3>\n<p>Prof. Marc Bonten (UMC Utrecht and CEO of Ecraid): \u201cEcraid has been established to enhance our capacity in Europe to mount a rapid clinical research response to any new infectious disease threat. Monkeypox may become such a threat, and that\u2019s why we have started preparations for clinical studies now.\u201d<\/p>\n<p>Prof. Yazdan Yazdanpannah (ANRS\/Inserm): \u201cThreats related to new emerging pathogens or re-emerging infectious diseases appear regularly and the frequency of their occurrence is increasing. This is again illustrated by the unprecedented and unexpected outbreak of human monkeypox cases across Europe, the Americas, and Australia. A United Europe of Research is key to respond to epidemics\/pandemics. Research infrastructures such as Ecraid and its partner networks EU-RESPONSE and VACCELERATE are very important tools of response.\u201d<\/p>\n<p>Prof. Peter Horby (Oxford University): \u201cThe unanticipated emergence of monkeypox outside of Africa is a perfect case-study of how threats anywhere can become threats everywhere and exemplifies the need to work as a global community to identify and counter all infectious disease problems, wherever they occur and whomever they affect.\u201d<\/p>\n<p>Prof. Marion Koopmans (Erasmus MC, Rotterdam): \u201cWhile we do not foresee a surge of monkeypox cases in the near future, preparedness does require scenario thinking and preparing for those scenarios. In Ecraid, we do that for possible trajectories that may evolve if the current public health response does not lead to containment of the outbreak.\u201d<\/p>\n<p>Prof. Herman Goossens (Antwerp University): \u201cThe European clinical trial networks, expanded during the COVID-19 pandemic thanks to significant EU funding, are providing the sustainable infrastructures for the response to the monkeypox threat.\u201d<\/p>\n<h3>About Ecraid<\/h3>\n<p>The European Clinical Research Alliance for Infectious Diseases (Ecraid) is a not-for profit foundation that advances clinical research in the field of infectious diseases by establishing a long-term, financially self-sustainable, clinical research network in Europe. Headquartered in Utrecht, the Netherlands, Ecraid is the first network of its kind in Europe to offer a single point of access to a pan-European clinical research network for infectious diseases and spans 1,100 clinical sites and 900 laboratories across 42 countries. For more information, please visit\u00a0<a href=\"http:\/\/www.ecraid.eu\/\" target=\"_blank\" rel=\"noopener\">www.ecraid.eu<\/a>.<\/p>\n<p><a href=\"https:\/\/ecraid.eu\/news\/european-response-monkeypox-virus-outbreak\" target=\"_blank\" rel=\"noopener\"><strong>ECRAID PRESS RELEASE<\/strong><\/a><\/p>\n<\/div><\/section><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-3b8mw-b506a38e8d00a7f4906eea669cebc6be\">\n.flex_column.av-3b8mw-b506a38e8d00a7f4906eea669cebc6be{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-3b8mw-b506a38e8d00a7f4906eea669cebc6be av_one_fifth  avia-builder-el-6  el_after_av_one_full  el_before_av_one_fifth  first flex_column_div av-zero-column-padding  column-top-margin'     ><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-2lzlw-3d25ff9ce16d4f57844d3b5b4e0627c5\">\n.flex_column.av-2lzlw-3d25ff9ce16d4f57844d3b5b4e0627c5{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-2lzlw-3d25ff9ce16d4f57844d3b5b4e0627c5 av_one_fifth  avia-builder-el-7  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  column-top-margin'     ><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-7tlo-f8416bb2afc61a4a130355b19410e269\">\n.flex_column.av-7tlo-f8416bb2afc61a4a130355b19410e269{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-7tlo-f8416bb2afc61a4a130355b19410e269 av_one_fifth  avia-builder-el-8  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  column-top-margin'     ><div  class='av-social-sharing-box av-k0i4kjks-6d3450111d8e25130dca06d4190760bd av-social-sharing-box-minimal  avia-builder-el-9  avia-builder-el-no-sibling  av-social-sharing-box-fullwidth'><div class=\"av-share-box\"><ul class=\"av-share-box-list noLightbox\"><li class='av-share-link av-social-link-twitter avia_social_iconfont' ><a target=\"_blank\" aria-label=\"Share on X\" href='https:\/\/twitter.com\/share?text=Ecraid%20press%20release%20on%20European%20response%20to%20monkeypox%20virus%20outbreak&#038;url=https:\/\/www.value-dx.eu\/?p=3774' data-av_icon='\ue932' data-av_iconfont='entypo-fontello'  title='' data-avia-related-tooltip='Share on X'><span class='avia_hidden_link_text'>Share on X<\/span><\/a><\/li><li class='av-share-link av-social-link-linkedin avia_social_iconfont' ><a target=\"_blank\" aria-label=\"Share on LinkedIn\" href='https:\/\/linkedin.com\/shareArticle?mini=true&#038;title=Ecraid%20press%20release%20on%20European%20response%20to%20monkeypox%20virus%20outbreak&#038;url=https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/' data-av_icon='\ue8fc' data-av_iconfont='entypo-fontello'  title='' data-avia-related-tooltip='Share on LinkedIn'><span class='avia_hidden_link_text'>Share on LinkedIn<\/span><\/a><\/li><li class='av-share-link av-social-link-mail avia_social_iconfont' ><a  aria-label=\"Share by Mail\" href='mailto:?subject=Ecraid%20press%20release%20on%20European%20response%20to%20monkeypox%20virus%20outbreak&#038;body=https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/' data-av_icon='\ue805' data-av_iconfont='entypo-fontello'  title='' data-avia-related-tooltip='Share by Mail'><span class='avia_hidden_link_text'>Share by Mail<\/span><\/a><\/li><\/ul><\/div><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-1gk3g-e035d72a73a93486e640208771f4a074\">\n.flex_column.av-1gk3g-e035d72a73a93486e640208771f4a074{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-1gk3g-e035d72a73a93486e640208771f4a074 av_one_fifth  avia-builder-el-10  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  column-top-margin'     ><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-yzdo-63e3a9df4e270ed0fd52b6929706fb26\">\n.flex_column.av-yzdo-63e3a9df4e270ed0fd52b6929706fb26{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-yzdo-63e3a9df4e270ed0fd52b6929706fb26 av_one_fifth  avia-builder-el-11  el_after_av_one_fifth  avia-builder-el-last  flex_column_div av-zero-column-padding  column-top-margin'     ><\/div><\/div><\/div><\/div><!-- close content main div --><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-k0i590fy-427634ed8909a6d2106239c938ad0962\">\n.avia-section.av-k0i590fy-427634ed8909a6d2106239c938ad0962{\nbackground-color:#1b7ca4;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_3'  class='avia-section av-k0i590fy-427634ed8909a6d2106239c938ad0962 main_color avia-section-default avia-no-border-styling  avia-builder-el-12  el_after_av_section  avia-builder-el-last  avia-bg-style-scroll container_wrap fullsize'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-3774'><div class='entry-content-wrapper clearfix'>\n\n<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":152,"featured_media":3769,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-3774","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ecraid press release on European response to monkeypox virus outbreak - value-dx<\/title>\n<meta name=\"description\" content=\"Ecraid is assessing its readiness to respond in the event the monkeypox outbreak spreads further in Europe.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ecraid press release on European response to monkeypox virus outbreak - value-dx\" \/>\n<meta property=\"og:description\" content=\"Ecraid is assessing its readiness to respond in the event the monkeypox outbreak spreads further in Europe.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/\" \/>\n<meta property=\"og:site_name\" content=\"value-dx\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-14T07:29:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Leandra\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ValueDx\" \/>\n<meta name=\"twitter:site\" content=\"@ValueDx\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leandra\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/\"},\"author\":{\"name\":\"Leandra\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\"},\"headline\":\"Ecraid press release on European response to monkeypox virus outbreak\",\"datePublished\":\"2022-07-14T07:29:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/\"},\"wordCount\":2130,\"image\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/Value-dx-ecraid-press-release-image.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/\",\"name\":\"Ecraid press release on European response to monkeypox virus outbreak - value-dx\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/Value-dx-ecraid-press-release-image.png\",\"datePublished\":\"2022-07-14T07:29:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\"},\"description\":\"Ecraid is assessing its readiness to respond in the event the monkeypox outbreak spreads further in Europe.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/Value-dx-ecraid-press-release-image.png\",\"contentUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/Value-dx-ecraid-press-release-image.png\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2022\\\/07\\\/14\\\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/homepage\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ecraid press release on European response to monkeypox virus outbreak\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/\",\"name\":\"value-dx\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.value-dx.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\",\"name\":\"Leandra\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/author\\\/leandra\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ecraid press release on European response to monkeypox virus outbreak - value-dx","description":"Ecraid is assessing its readiness to respond in the event the monkeypox outbreak spreads further in Europe.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/","og_locale":"en_US","og_type":"article","og_title":"Ecraid press release on European response to monkeypox virus outbreak - value-dx","og_description":"Ecraid is assessing its readiness to respond in the event the monkeypox outbreak spreads further in Europe.","og_url":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/","og_site_name":"value-dx","article_published_time":"2022-07-14T07:29:45+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image.png","type":"image\/png"}],"author":"Leandra","twitter_card":"summary_large_image","twitter_creator":"@ValueDx","twitter_site":"@ValueDx","twitter_misc":{"Written by":"Leandra","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/#article","isPartOf":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/"},"author":{"name":"Leandra","@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d"},"headline":"Ecraid press release on European response to monkeypox virus outbreak","datePublished":"2022-07-14T07:29:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/"},"wordCount":2130,"image":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image.png","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/","url":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/","name":"Ecraid press release on European response to monkeypox virus outbreak - value-dx","isPartOf":{"@id":"https:\/\/www.value-dx.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/#primaryimage"},"image":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image.png","datePublished":"2022-07-14T07:29:45+00:00","author":{"@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d"},"description":"Ecraid is assessing its readiness to respond in the event the monkeypox outbreak spreads further in Europe.","breadcrumb":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/#primaryimage","url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image.png","contentUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image.png","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.value-dx.eu\/index.php\/2022\/07\/14\/ecraid-press-release-on-european-response-to-monkeypox-virus-outbreak-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.value-dx.eu\/index.php\/homepage\/"},{"@type":"ListItem","position":2,"name":"Ecraid press release on European response to monkeypox virus outbreak"}]},{"@type":"WebSite","@id":"https:\/\/www.value-dx.eu\/#website","url":"https:\/\/www.value-dx.eu\/","name":"value-dx","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.value-dx.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d","name":"Leandra","url":"https:\/\/www.value-dx.eu\/index.php\/author\/leandra\/"}]}},"jetpack_featured_media_url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2022\/07\/Value-dx-ecraid-press-release-image.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts\/3774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/users\/152"}],"replies":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/comments?post=3774"}],"version-history":[{"count":0,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts\/3774\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/media\/3769"}],"wp:attachment":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/media?parent=3774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/categories?post=3774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/tags?post=3774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}